- Using conditionally reprogrammed (CR) cells instead of genetically engineered cell lines for in-vitro studies. Many of our cell lines have matching PDX models.
- Bridging in-vitro to in-vivo studies by validating your compounds using MiniPDX, an in-vivo version of an organoid assay. Drug sensitivity results in 7 days.
- Preparing your IND filing with the gold standard PDX study.
- Leveraging MiniPDX and fresh patient samples in a biomarker identification study, to inform patient stratification and recruitment strategy for clinical trials
Fig. New, optimized R&D roadmap using LIDE Functional Diagnosis platform and conditional reprogramed (CR) cells